Navigation Links
Biochemical signature predicts progression to Alzheimer's disease
Date:12/14/2011

A study led by Research Professor Matej Oreič from VTT Technical Research Centre of Finland suggests that Alzheimer's disease is preceded by a molecular signature indicative of hypoxia and up-regulated pentose phosphate pathway. This indicator can be analysed as a simple biochemical assay from a serum sample months or even years before the first symptoms of the disease occur. In a healthcare setting, the application of such an assay could therefore complement the neurocognitive assessment by the medical doctor and could be applied to identify the at-risk patients in need of further comprehensive follow-up.

Alzheimer's disease (AD) is a growing challenge to the health care systems and economies of developed countries with millions of patients suffering from this disease and increasing numbers of new cases diagnosed annually with the increasing ageing of populations.

The progression of Alzheimer's disease (AD) is gradual, with the subclinical stage of illness believed to span several decades. The pre-dementia stage, also termed mild cognitive impairment (MCI), is characterised by subtle symptoms that may affect complex daily activities. MCI is considered as a transition phase between normal aging and AD. MCI confers an increased risk of developing AD, although the state is heterogeneous with several possible outcomes, including even improvement back to normal cognition.

What are the molecular changes and processes which define those MCI patients who are at high risk of developing AD? The teams led by Matej Oreič from VTT and Hilkka Soininen from the University of Eastern Finland set out to address this question, and the results were published on 13th Dec. 2011 in Translational Psychiatry.

The team used metabolomics, a high-throughput method for detecting small metabolites, to produce profiles of the serum metabolites associated with progression to AD. Serum samples were collected at baseline when the patients were diagnosed with AD, MCI, or identified as healthy controls. 52 out of 143 MCI patients progressed to AD during the follow-up period of 27 months on average. A molecular signature comprising three metabolites measured at baseline was derived which was predictive of progression to AD. Furthermore, analysis of data in the context of metabolic pathways revealed that pentose phosphate pathway was associated with progression to AD, also implicating the role of hypoxia and oxidative stress as early disease processes.

The unique study setting allowed the researchers to identify the patients diagnosed with MCI at baseline who later progressed to AD and to derive the molecular signature which can identify such patients at baseline.

Though there is no current therapy to prevent AD, early disease detection is vital both for delaying the onset of the disease through pharmacological treatment and/or lifestyle changes and for assessing the efficacy of potential AD therapeutic agents. The elucidation of early metabolic pathways associated with progression to Alzheimer's disease may also help in identifying new therapeutic avenues.


'/>"/>

Contact: Matej Oresic
matej.oresic@vtt.fi
358-207-224-491
VTT Technical Research Centre of Finland
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
2. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
3. News tips from the May/June issue of Physiological and Biochemical Zoology
4. Biochemical and Molecular Engineering XVII Conference
5. NutriLuxe Offers Personal, At-Home Body Biochemical Balance Test
6. Toronto researchers obtain detailed molecular signature for Tankyrase
7. Lung cancer signatures in blood samples may aid in early detection
8. Penn researchers find neural signature of mental time travel
9. Researchers home in on genetic signature of esophageal cancer
10. Genomic signature in post-menopausal women may explain why pregnancy reduces breast cancer risk
11. Molecular signatures may aid fight against pediatric liver disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on June ... medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and professional ...
(Date:6/23/2017)... Providence, RI (PRWEB) , ... June 23, 2017 ... ... Community Care Network today announced the launch of Care Management Alerts and Dashboards, ... for 140,000 patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards ...
(Date:6/23/2017)... ... , ... Studies show evidence that carotenoids and antioxidants derived either from the ... patients. , But how often do ophthalmologists and optometrists in Sweden recommend the use ... or with early symptoms of AMD? A study published recently in Dove ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal ... prefer to read it, and some people don't like it at all. FindaTopDoc took ... they found: , Erotic literature can give readers a taste of their deepest, darkest ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 7, 2017  Novavax, Inc., (Nasdaq: NVAX ) ... 2 trials of its RSV F protein recombinant nanoparticle vaccine ... have been published in the journal Vaccine ... in prior scientific conferences). The Company previously announced top ... is developing the RSV F Vaccine with the goal of ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a ... today announced new findings demonstrating positive biochemical outcomes related ... System One™. The data will be presented at the ... Madrid, Spain . The ... Home Dialysis Network in Europe ...
(Date:5/29/2017)... -- Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), ... selection of stem cells, today provided a corporate update ... March 31 st , 2017. "We ... quarter of 2017," said Dr. Shai Yarkoni, Chief Executive ... of the first blood cancer patient in the recently ...
Breaking Medicine Technology: